Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy (original) (raw)

British Journal of Cancer volume 76, pages 1099–1105 (1997)Cite this article

Abstract

Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and prednisolone 40 mg per day orally for 5 days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP was reserved for those women whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women who still have an appalling prognosis after preoperative chemotherapy or hormone therapy.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 24 print issues and online access

$259.00 per year

only $10.79 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK
    DA Cameron

Authors

  1. DA Cameron
  2. EDC Anderson
  3. P Levack
  4. RA Hawkins
  5. TJ Anderson
  6. RCF Leonard
  7. APM Forrest
  8. U Chetty

Rights and permissions

About this article

Cite this article

Cameron, D., Anderson, E., Levack, P. et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy.Br J Cancer 76, 1099–1105 (1997). https://doi.org/10.1038/bjc.1997.514

Download citation

This article is cited by